According to Zacks Research, Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) is a better value stock compared to Zoetis (ZTS) based on its superior Zacks Rank of #1 (Strong Buy) versus ZTS's #2 (Buy) and a Value grade of B compared to ZTS's C. DSNKY's lower forward P/E ratio of 21.96, PEG ratio of 1.54, and P/B ratio of 4.63 further support this assessment, indicating it may be undervalued relative to ZTS, which has a forward P/E of 27.23, a PEG ratio of 2.82, and a P/B of 16.32.
Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY) presents a more compelling value proposition compared to Zoetis (ZTS) within the Medical - Drugs sector, according to an analysis utilizing the Zacks Rank system and Style Scores. DSNKY holds a Zacks Rank of #1 (Strong Buy), indicating positive earnings estimate revision trends and an improving earnings outlook, superior to ZTS's Rank of #2 (Buy). In terms of valuation, DSNKY scores a Value grade of B, while ZTS has a C. This is supported by DSNKY's forward P/E ratio of 21.96, which is lower than ZTS's 27.23. Furthermore, DSNKY's PEG ratio of 1.54, which incorporates expected earnings growth, is more attractive than ZTS's 2.82. Another key metric, the P/B ratio, also favors DSNKY at 4.63 compared to ZTS's significantly higher 16.32. These combined factors suggest DSNKY is currently the superior value option based on its fundamental valuation metrics and earnings outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
